Payment overview · 2025
General Payments
$38.37
2 reported records · 2 companies
Healthcare provider profile · identity verified
Kevin Snow, DO
Allopathic & Osteopathic Physicians|Internal Medicine · HOLYOKE, MA · NPI 1447342183
Verified facts
What the public records show
CMS Open Payments records show Kevin Snow, DO received $38.37 in general payments during 2025 across 2 reported records.
Stryker Corporation accounted for 62.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 397 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Stryker Corporation | Unresolved — no canonical attribution shown | $23.84 | 62.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.53 | 37.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $38.37 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $23.84 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 397 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
397 | 25 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clozapine | Clozapine | 662 | 27 |
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 50 |
| Levothyroxine Sodium | Levothyroxine Sodium | 424 | 43 |
| Eliquis | Apixaban | 397 | 25 |
| Lactulose | Lactulose | 391 | 45 |
| Gabapentin | Gabapentin | 382 | 29 |
| Metformin Hcl | Metformin Hcl | 344 | 32 |
| Levetiracetam | Levetiracetam | 325 | 28 |
| Xifaxan | Rifaximin | 315 | 11 |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 281 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 277 | 34 |
| Risperidone | Risperidone | 273 | 22 |
| Lisinopril | Lisinopril | 268 | 23 |
| Omeprazole | Omeprazole | 256 | 28 |
| Propranolol Hcl | Propranolol Hcl | 251 | 22 |
| Haloperidol | Haloperidol | 232 | 17 |
| Diazepam | Diazepam | 228 | 22 |
| Furosemide | Furosemide | 225 | 19 |
| Oxcarbazepine | Oxcarbazepine | 214 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 212 | 22 |
| Divalproex Sodium | Divalproex Sodium | 201 | 14 |
| Carbamazepine Er | Carbamazepine | 184 | suppressed |
| Gemfibrozil | Gemfibrozil | 183 | 13 |
| Amlodipine Besylate | Amlodipine Besylate | 182 | 25 |
| Mirtazapine | Mirtazapine | 173 | 16 |
| Perphenazine | Perphenazine | 164 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 160 | 16 |
| Famotidine | Famotidine | 159 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 153 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 15 |
| Trazodone Hcl | Trazodone Hcl | 151 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 136 | 17 |
| Xarelto | Rivaroxaban | 135 | suppressed |
| Pregabalin | Pregabalin | 134 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 121 | 20 |
| Potassium Chloride | Potassium Chloride | 119 | 12 |
| Olanzapine | Olanzapine | 106 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 104 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 86 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 83 | 14 |
| Finasteride | Finasteride | 80 | suppressed |
| Simvastatin | Simvastatin | 80 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 46 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 73 | suppressed |
| Lorazepam | Lorazepam | 72 | 17 |
| Lamotrigine | Lamotrigine | 71 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 69 | suppressed |
| Januvia | Sitagliptin Phosphate | 69 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 67 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 67 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 11 |
| Topiramate | Topiramate | 63 | suppressed |
| Ibuprofen | Ibuprofen | 62 | 15 |
| Carvedilol | Carvedilol | 59 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 59 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 57 | 43 |
| Midodrine Hcl | Midodrine Hcl | 55 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 54 | suppressed |
| Myrbetriq | Mirabegron | 53 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 51 | suppressed |
| Clobazam | Clobazam | 50 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 45 | 19 |
| Aripiprazole | Aripiprazole | 44 | suppressed |
| Losartan Potassium | Losartan Potassium | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | suppressed |
| Prednisone | Prednisone | 43 | 31 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | suppressed |
| Atenolol | Atenolol | 41 | suppressed |
| Baclofen | Baclofen | 40 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 16 |
| Glipizide | Glipizide | 37 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 36 | 33 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Latanoprost | Latanoprost | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 35 | suppressed |
| Lacosamide | Lacosamide | 35 | suppressed |
| Nystatin | Nystatin | 34 | 15 |
| Sodium Fluoride | Fluoride (Sodium) | 34 | 14 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 33 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Amantadine | Amantadine Hcl | 32 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 31 | suppressed |
| Nystop | Nystatin | 31 | 15 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 29 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 29 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 27 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Olanzapine Odt | Olanzapine | 25 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Calcitriol | Calcitriol | 23 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Posaconazole | Posaconazole | 20 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Insulin Lispro | Insulin Lispro | 17 | suppressed |
| Levemir Flexpen | Insulin Detemir | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 17 | suppressed |
| Carbamazepine | Carbamazepine | 16 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Humalog | Insulin Lispro | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Procrit | Epoetin Alfa | 15 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Norethindrone Acetate | Norethindrone Acetate | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Bicalutamide | Bicalutamide | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Dovato | Dolutegravir Sodium/Lamivudine | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Ingrezza | Valbenazine Tosylate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Lubiprostone | Lubiprostone | 11 | suppressed |
| Memantine Hcl | Memantine Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ritonavir | Ritonavir | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $38.37 · 2 records | Stryker Corporation | CT THROMBECTOMY SYSTEM KIT, ELIQUIS, FLOWTRIEVER CATHETER, S, NURTEC ODT, PAXLOVID | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error